PARP抑制剂在高级别浆液性输卵管卵巢癌的不同遗传背景中对免疫反应有不同调节作用。
PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma.
作者信息
Doro Pereira Luiza, Wielgos-Bonvallet Monica, Misirlioglu Selim, Khodadai-Jamayran Alireza, Jelinic Petar, Levine Douglas A
机构信息
Division of Gynecologic Oncology, Department of OB/GYN, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York.
Department of Pathology, Applied Bioinformatics Laboratories, NYU School of Medicine, New York, New York.
出版信息
Cancer Res Commun. 2025 Feb 1;5(2):339-348. doi: 10.1158/2767-9764.CRC-24-0515.
This work highlights how different PARPis, especially talazoparib, modulate immune-related gene expression in ovarian cancer cells, independent of the cGAS-STING pathway. These findings may improve our understanding of how different PARPis affect the immune system in various genetic backgrounds.
这项研究突出了不同的聚（ADP-核糖）聚合酶抑制剂（PARPis），尤其是他拉唑帕尼，如何在不依赖于环鸟苷酸-腺苷酸合成酶-干扰素基因刺激蛋白（cGAS-STING）途径的情况下，调节卵巢癌细胞中与免疫相关的基因表达。这些发现可能会增进我们对不同PARPis如何在各种基因背景下影响免疫系统的理解。
Zotero 插件